From: The burden of hepatitis C in Europe from the patients’ perspective: a survey in 5 countries
HCV never treated | Matched controls | p-value | |||
---|---|---|---|---|---|
(n = 139) | (n = 139) | ||||
M | SD | M | SD | ||
Work productivity & activity impairment | |||||
Absenteeism | 6.67% | 18.26% | 2.84% | 13.36% | .157 |
Presenteeism | 24.84% | 30.07% | 12.86% | 21.28% | .006 |
Overall work impairment | 28.65% | 32.94% | 14.75% | 24.57% | .004 |
Activity impairment | 31.73% | 30.57% | 29.28% | 31.48% | .374 |
Healthcare resource utilization | |||||
Physician visits | 19.54 | 24.62 | 12.06 | 16.80 | .001 |
ER visits | 0.46 | 1.90 | 0.35 | 1.15 | .986 |
Hospitalizations | 0.36 | 1.16 | 0.19 | 0.99 | .120 |
Quality of life (SF-12v2) | |||||
MCS | 44.72 | 10.43 | 45.93 | 11.64 | .361 |
PCS | 43.49 | 10.26 | 45.99 | 10.72 | .048 |
Health utility | 0.68 | 0.13 | 0.71 | 0.15 | .080 |